secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRONWOOD PHARMACEUTICALS INC (IRWD)
CIK:        0001446847
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0001104659-24-024345
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ironwood reports FY2023 GAAP net loss of $1.0B; LINZESS sales $1.1B (+7%)
-------------------------------------------------------------------------

- FY2023 total revenue $442.7M; LINZESS collaboration revenue $430M; Q4 revenue $117.6M.
- FY2023 GAAP net loss attributable to Ironwood $1.002B ($6.45 diluted loss/share), vs FY2022 net income $175M.
- LINZESS U.S. net sales $1.1B (+7% YoY), prescription demand +10% YoY; pediatric IBS-C approval in June 2023.
- Expects topline STARS Phase 3 study of apraglutide in SBS-IF in March 2024; CNP-104 Phase 2 data in Q3 2024.
- FY2023 adjusted EBITDA loss $884.8M (includes impairment), vs positive $251.8M in FY2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1446847/000110465924024345/0001104659-24-024345-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1446847/000110465924024345/tm246124d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-024345

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer